Total Neoadjuvant Therapy Versus Conventional Neoadjuvant Therapy for Rectal Cancer: Cost Analysis in a Public Healthcare System
ANZ Journal of Surgery · 2025
DOI: 10.1111/ans.70169 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift ANZ Journal of Surgery, 2025. Verfasst von Ishraq Murshed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Surgery, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, Health Care Costs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
Total neoadjuvant therapy (TNT) has become the standard of care in locally advanced rectal cancer, but its economic impact is unclear. This study compares the cost of TNT with conventional neoadjuvant therapy (CNT), consisting of either short‐course radiotherapy or long‐course chemoradiotherapy, within a universally funded public healthcare system. Methodology A trial‐based costing analysis was conducted from a third‐party payer's perspective with a 2‐year time horizon, following CHEERS guidelines. Consecutive patients with rectal cancer treated with neoadjuvant therapy from 2014 to 2023 were extracted from a multi‐institutional database. Inpatient, outpatient, imaging and pathology resource costs were extracted and adjusted to 2024 AUD with a 5% discount rate. Primary outcomes were overall cost per cohort and mean per patient cost. Secondary outcomes were overall and mean cost per cost category. Sensitivity analysis explored the influence of discount rates and inflation methods.
Results
Of 115 eligible patients, 60 (52.2%) received CNT and 55 (47.8%) received TNT. Overall treatment costs for the cohorts were $8 429 710.66 (CNT) and $6 992 616.67 (TNT), with mean per patient costs of $140 495.18 (CNT) and $127 138.48 (TNT). Overall per patient costs were $13 356.70 (9.51%) lower for TNT patients, mainly driven by lower mean inpatient costs ($78 523.53 vs. $96 843.08, 18.9%). TNT increased outpatient ($43 001.18 vs. $39 376.12, 9.21%), imaging ($4179.13 vs. $2973.61, 40.5%) and pathology ($1434.65 vs. $1302.38, 10.1%) costs. The results were robust to sensitivity analysis.
Conclusion
TNT is less costly than CNT within a universally funded public healthcare system, primarily due to reduced inpatient costs associated with higher rates of organ preservation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Discipline of Surgery, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
- Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
ORCID-Profile: Ishraq Murshed, Sergei Bedrikovetski, Ishmam Murshed, Zachary Bunjo, Tracy Fitzsimmons, Tarik Sammour
Zitieren
APA
Murshed, I., Bedrikovetski, S., Murshed, I., Bunjo, Z., Fitzsimmons, T., Thomas, M., & Sammour, T. (2025). Total Neoadjuvant Therapy Versus Conventional Neoadjuvant Therapy for Rectal Cancer: Cost Analysis in a Public Healthcare System. ANZ Journal of Surgery. https://doi.org/10.1111/ans.70169
Vancouver
Murshed I, Bedrikovetski S, Murshed I, Bunjo Z, Fitzsimmons T, Thomas M, et al. Total Neoadjuvant Therapy Versus Conventional Neoadjuvant Therapy for Rectal Cancer: Cost Analysis in a Public Healthcare System. ANZ Journal of Surgery. 2025. doi:10.1111/ans.70169
BibTeX
@article{Murshed2025,
author = {Murshed, Ishraq and Bedrikovetski, Sergei and Murshed, Ishmam and Bunjo, Zachary and Fitzsimmons, Tracy and Thomas, Michelle and Sammour, Tarik},
title = {Total Neoadjuvant Therapy Versus Conventional Neoadjuvant Therapy for Rectal Cancer: Cost Analysis in a Public Healthcare System},
journal = {ANZ Journal of Surgery},
year = {2025},
doi = {10.1111/ans.70169}
}
EUVIMED